1型糖尿病成人从间歇扫描式转向实时持续葡萄糖监测的效果:随机ALERTT1试验24个月结果
ALERTT1试验在比利时6家医院纳入254例既往使用无警报间歇扫描式持续葡萄糖监测(isCGM)的1型糖尿病成人,随机分至带警报实时持续葡萄糖监测(rtCGM)组或继续isCGM组;6个月后对照组也换用rtCGM。扩展研究至24个月显示,换用rtCGM后目标范围内时间(TIR)和HbA1c持续改善,低血糖担忧评分下降,支持在1型糖尿病成人中使用rtCGM。
要点
- 换用rtCGM后TIR从约52%升至约63%,并维持至24个月。
- 换用rtCGM后HbA1c下降约0.4–0.5个百分点,维持至24个月。
- 换用rtCGM后严重低血糖从31.0降至3.3例/100患者年。
核心结论
- 从无警报isCGM换用带警报rtCGM后,血糖控制和低血糖担忧在24个月内显著改善,支持在1型糖尿病成人照护中使用rtCGM。
研究设计与样本
- 6个月、双臂、平行组、非盲、随机对照试验,在比利时6家医院开展,纳入254例18岁及以上既往使用isCGM的1型糖尿病成人,按1:1随机分配至带警报rtCGM组(n=127)或无警报isCGM组(n=127)。
主要发现
- is-rtCGM组TIR从rtCGM开始(第6个月)的51.8%(95%CI 49.1-54.5)升至第12个月的63.5%(60.7-66.3),并维持至第24个月(变化11.7个百分点[9.4-14.0];p<0.0001)。
- rt-rtCGM组TIR从rtCGM开始(第0个月)的52.5%(95%CI 49.8-55.1)升至第12个月的63.0%(60.3-65.8),并维持至第24个月(变化10.5个百分点[8.2-12.8];p<0.0001)。
- is-rtCGM组HbA1c从第6个月的7.4%(57 mmol/mol)降至第24个月的6.9%(52 mmol/mol),变化-0.54个百分点(95%CI -0.64至-0.44;-5 mmol/mol[95%CI -6至-4];p<0.0001)。
- rt-rtCGM组HbA1c从第0个月的7.4%(57 mmol/mol)降至第24个月的7.0%(53 mmol/mol),变化-0.43个百分点(95%CI -0.53至-0.33;-4 mmol/mol[95%CI -5至-3];p<0.0001)。
- HFS-担忧评分变化:is-rtCGM组为-2.67分(第24个月vs第6个月;p=0.0008),rt-rtCGM组为-5.17分(第24个月vs第0个月;p<0.0001);临床显著低血糖时间在第12个月后两组均无变化;换用rtCGM后严重低血糖从31.0降至3.3例/100患者年。
关键数值与推荐
- is-rtCGM组112/119例(94%)完成24个月试验,rt-rtCGM组117/123例(95%)完成24个月试验。
临床怎么用
- 作者认为,从无警报isCGM换用带警报rtCGM后血糖控制和低血糖担忧显著改善,支持在1型糖尿病成人照护中使用rtCGM。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Comparing Continuous With Flash Glucose Monitoring In Adults With Type 1 Diabetes (ALERTT1) examined whether switching from first-generation intermittently scanned continuous glucose monitoring (isCGM) without alerts to real-time continuous glucose monitoring (rtCGM) with alert functionality offers additional benefits to adults with type 1 diabetes. The extension of the randomised ALERTT1 trial assessed the effect of switching from isCGM to rtCGM up to 24 months. METHODS: In this 6-month, double-arm, parallel-group, non-masked, randomised, controlled trial, done across six hospitals in Belgium, 254 adults aged 18 years or older with type 1 diabetes previously using isCGM were randomly assigned (1:1) to rtCGM with alerts (intervention; n=127) or isCGM without alerts (control; n=127). Upon completion of the 6-month trial, the control group switched to rtCGM (is-rtCGM group), and the intervention group continued rtCGM (rt-rtCGM group). The extension focused on within-group changes in time in range (TIR; 3·9-10·0 mmol/L; primary outcome), HbA1c, time in clinically significant hypoglycaemia (<3·0 mmol/L), and Hypoglycaemia Fear Survey worry (HFS-worry) score (all prespecified key secondary outcomes). Mean within-group change versus the start of rtCGM is reported, with a positive value referring to a lower value at start of rtCGM. This trial is registered at ClinicalTrials.gov (NCT03772600). FINDINGS: 119 participants were assigned to the is-rtCGM group of whom 112 (94%) completed the 24-month trial, and 123 participants were assigned to the rt-rtCGM group of whom 117 (95%) completed the 24-month trial. TIR increased from 51·8% (95% CI 49·1-54·5) at start of rtCGM (month 6) to 63·5% (60·7-66·3) at month 12 in the is-rtCGM group, and remained stable up to month 24 (change 11·7 percentage points [pp] [9·4-14·0; p<0·0001). In the rt-rtCGM group, TIR increased from 52·5% (95% CI 49·8-55·1) at start of rtCGM (month 0) to 63·0% (60·3-65·8) at month 12, also remaining stable up to month 24 (change 10·5 pp [8·2-12·8]; p<0·0001). HbA1c decreased from 7·4% (57 mmol/mol; month 6) to 6·9% (52 mmol/mol) at month 24 (change -0·54 pp [95% CI -0·64 to -0·44]; -5 mmol/mol [95% CI -6 to -4]; p<0·0001) in the is-rtCGM group, and from 7·4% (57 mmol/mol; month 0) to 7·0% (53 mmol/mol) at month 24 (change -0·43 pp [95% CI -0·53 to -0·33]; -4 mmol/mol [95% CI -5 to -3]; p<0·0001) in the rt-rtCGM group. The change in HFS-worry score was -2·67 (month 24 vs month 6; p=0·0008) in the is-rtCGM group and -5·17 points (month 24 vs month 0; p<0·0001) in the rt-rtCGM group. Time in clinically significant hypoglycaemia was unchanged in both groups after month 12. Severe hypoglycaemia decreased from 31·0 to 3·3 per 100 patient-years after switching to rtCGM. INTERPRETATION: Glycaemic control and hypoglycaemia worry improved significantly up to 24 months after switching from isCGM without alerts to rtCGM with alerts, supporting the use of rtCGM in the care of adults with type 1 diabetes. FUNDING: Dexcom.
引用
- Visser MM, Charleer S, Fieuws S, et al. Effect of switching from intermittently scanned to real-time continuous glucose monitoring in adults with type 1 diabetes: 24-month results from the randomised ALERTT1 trial. Lancet Diabetes Endocrinol. 2023. PMID: 36702566. doi:10.1016/S2213-8587(22)00352-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。